Unidentified Analyst: Hi, this is John on for Tim. Thanks for taking our question and congrats on a successful 2022 and looking forward to an exciting 2023. So I know recently you’ve been discussing how some additional education is required around BELBUCAs profile to accelerate growth of that franchise. Can you just talk to us a little bit about how those efforts are going and how you see the growth of the BELBUCA franchise ramping up through 2023 as those efforts come together? Thanks.
Joe Ciaffoni: Sure. Thanks for the question, John. I’m going to ask Scott to answer.
Scott Dreyer: Yes, thanks, John. Yes. So when we look at 2023 and kind of the performance trend and where we’re heading, what we believe is on a full year basis we’re positioned for growth. And the reason related to your training comment is, last year with the acquisition of BDSI, we went through a lot of disruption, there was a lot of learning around the brand. And what I’d say is similar to, to what I articulate in the fourth quarter call, like we’re starting to get our sea legs under us. Our people are stable in their territories; our sales reps are comfortable with the brand. And some for those reasons, combined with the other commercial actions we’re taking in 2023. That’s why we believe on a full year basis, we can see growth for BELBUCA.
Unidentified Analyst: All right, thanks so much for that caller.
Scott Dreyer: Thanks, John.
Operator: And our next question comes from Brandon Folkes with Cantor Fitzgerald. Please state your question.
Brandon Folkes: Hi, thanks for taking my questions and congratulations on all the progress this year, beg a pardon 2022. Scott, thanks for the details on the Xtampza and BELBUCA prescription growth drivers. Can you just elaborate how you see the addressable market evolving? I think we continue to see the headwinds in the Xtampza and branded of OxyContin ER market. So just any color there just in terms of how you view the overall market, I guess, with Xtampza and BELBUCA checking out this year and maybe going forward.
Joe Ciaffoni: Yes, Brandon. So this is Joe, I’ll start on that and then Scott may have some additional perspective to provide. Look, when we when we look at Xtampza ER and BELBUCA the first thing that I would emphasize is we think there is plenty of room within the market for both of these important differentiated brands to continue to grow. When we look out at the market over the next five years, we believe that you’ll start to see a moderation of the decline going to the mid-to-low single digits. I think the strongest piece of evidence to support that would be where now we would be approaching upon the use of opioids of the early 2000s, which was significant of when pain was called out as a fifth vital sign. What we know for sure isn’t going to change unfortunately, is the number of people who are experiencing pain that have chronic pain and the high intensity nature of which opioids will continue to be a cornerstone of therapy.
So from a, oxycodone portion of the market, we are not concerned we are focused on replacing OxyContin utilization and then as you know, the buprenorphine portion of the market is growing. And certainly we believe BELBUCA is a differentiated schedule three product, in particular relative to Butrans from a dose ranging perspective. So we think the dynamics are there for continued growth.
